blonanserin has been researched along with haloperidol in 12 studies
| Studies (blonanserin) | Trials (blonanserin) | Recent Studies (post-2010) (blonanserin) | Studies (haloperidol) | Trials (haloperidol) | Recent Studies (post-2010) (haloperidol) |
|---|---|---|---|---|---|
| 121 | 21 | 93 | 20,330 | 1,753 | 3,294 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furukawa, K; Hino, K; Karasawa, T; Kurumiya, S; Noda, Y; Ochi, Y; Oka, M; Une, T | 1 |
| Kurumiya, S; Miura, Y; Noda, Y; Oka, M | 1 |
| Fukuda, A; Matsuno, T; Matsuo, T; Motomura, H; Shoge, T; Tashiro, N; Tatebayashi, H; Yokota, K | 1 |
| Garcia, E; Nakamura, H; Peris, F; Robert, M; Sato, N; Terazawa, Y | 1 |
| Imaki, J; Ohno, Y; Okano, M; Okumura, T; Shimizu, S; Tatara, A | 1 |
| Baba, S; Enomoto, T; Ikeda, K; Murai, T; Nakako, T; Ono, M; Shimizu, I | 1 |
| Masui, A; Minamimoto, S; Mizobe, Y; Mizuguchi, Y; Ochiai, M; Ohno, Y; Shimizu, S; Tamura, M; Tatara, A | 1 |
| Huang, M; Kwon, S; Meltzer, HY; Miyauchi, M; Oyamada, Y; Rajagopal, L | 1 |
| Harvey, PD; Murasaki, M; Nakamura, H | 1 |
| Hashimoto, N; Ishikawa, S; Ito, YM; Kusumi, I; Okubo, R; Sato, N; Sawagashira, R; Yamamura, R | 1 |
| Nakamura, T; Sasayama, D; Takahashi, K; Washizuka, S; Yokotsuka-Ishida, S | 1 |
| Ando, K; Suzuki, A; Yoshida, H | 1 |
2 trial(s) available for blonanserin and haloperidol
| Article | Year |
|---|---|
The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol; Humans; International Cooperation; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Severity of Illness Index; Young Adult | 2009 |
Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Tolerance; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Piperidines; Schizophrenia; Weight Gain | 2019 |
10 other study(ies) available for blonanserin and haloperidol
| Article | Year |
|---|---|
Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Biogenic Monoamines; Clozapine; Dogs; Dopamine D2 Receptor Antagonists; Guinea Pigs; Haloperidol; Macaca fascicularis; Male; Mice; Mice, Inbred Strains; Neurotransmitter Uptake Inhibitors; Piperazines; Piperidines; Prosencephalon; Radioligand Assay; Rats; Rats, Wistar; Receptors, Adrenergic, alpha; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists; Spiperone; Tritium | 1993 |
Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Body Temperature; Brain; Drug Synergism; Haloperidol; Male; Piperazines; Piperidines; Rats; Rats, Wistar; Receptors, Dopamine; Veratrine | 1993 |
The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics.
Topics: Animals; Antipsychotic Agents; Cells, Cultured; Chloride Channel Agonists; Chloride Channels; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Synergism; gamma-Aminobutyric Acid; Ganglia, Spinal; Haloperidol; Incidence; Membrane Potentials; Piperazines; Piperidines; Quetiapine Fumarate; Rats; Rats, Wistar; Seizures | 2002 |
Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Haloperidol; Male; Mice; Mice, Inbred Strains; Nucleus Accumbens; Piperazines; Piperidines; Proto-Oncogene Proteins c-fos; Pyridines; Serotonin 5-HT2 Receptor Antagonists | 2010 |
The serotonin 5-HT₁A receptor agonist tandospirone improves executive function in common marmosets.
Topics: Animals; Antipsychotic Agents; Callithrix; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Executive Function; Haloperidol; Isoindoles; Male; Piperazines; Piperidines; Psychological Tests; Psychotropic Drugs; Pyrimidines; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D1; Risperidone; Serotonin 5-HT1 Receptor Agonists | 2015 |
Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin.
Topics: Animals; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Catalepsy; Corpus Striatum; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Injections, Subcutaneous; Male; Mice; Nucleus Accumbens; Oncogene Proteins v-fos; Piperazines; Piperidines; Pyridines | 2015 |
Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement.
Topics: Acetylcholine; Animals; Benzopyrans; Brain Chemistry; Cerebral Cortex; Dopamine; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Fluorenes; Haloperidol; Male; Mice; Mice, Inbred C57BL; Nootropic Agents; Oxazines; Phencyclidine; Piperazines; Piperidines; Rats, Long-Evans; Receptors, Dopamine D3 | 2015 |
The type rather than the daily dose or number of antipsychotics affects the incidence of hyperglycemic progression.
Topics: Adult; Antipsychotic Agents; Clozapine; Dibenzothiepins; Female; Haloperidol; Humans; Hyperglycemia; Incidence; Japan; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Schizophrenia | 2022 |
Improved response to electroconvulsive therapy after switching from haloperidol to blonanserin in a patient with treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Electroconvulsive Therapy; Haloperidol; Humans; Piperazines; Piperidines; Schizophrenia; Schizophrenia, Treatment-Resistant | 2022 |
Efficacy of blonanserin transdermal patch on terminal delirium in patients with respiratory diseases.
Topics: Antipsychotic Agents; Delirium; Dyspnea; Haloperidol; Humans; Retrospective Studies; Transdermal Patch | 2023 |